Innovations in Blood
Biomarker Discovery

Welcome to Sangui Bio

Innovating whole-blood proteomics with VeriPro, our biomarker discovery platform.

Explore ColoPro → About Sangui Bio
The platform

From a single drop to a clinical-grade proteomic readout.

The VeriPro platform pairs at-home microsampling with whole-blood proteomics. Biomarkers discovered against gold-standard reference tests become diagnostics that run on a simple fingerprick sample.

At-home fingerprick collection device
01 · Microsampling

At-home blood collection

A single 30 µL fingerprick whole-blood sample. No clinic visit, no prep, no fasting — mailed back at room temperature.

Reference disease test illustration
02 · Reference test

Gold-standard labelling

Participants undergo the reference disease test — colonoscopy, mammogram or CT — providing the labels needed for biomarker discovery.

Mass spectrometry instrument
03 · Proteomics

Whole-blood mass spectrometry

Samples are processed with Sangui Bio's proprietary preparation methods and analysed by DIA mass spectrometry, quantifying ~4,000 proteins per sample.

Protein analysis visualisation
04 · Biomarker panels

Diagnostic classifier

Computational analysis filters statistically significant proteins into a focused biomarker panel that correlates with disease status — the basis of an at-home blood diagnostic.

ColoPro at-home collection kit
ColoPro

A blood test for colorectal cancer surveillance.

ColoPro detects advanced precancerous polyps from a 30 µL fingerprick blood sample collected at home. The target population: 25 million Americans who have had polyps removed and need ongoing surveillance — a group with no validated blood-based alternative today.

Annual testing, ordered by the gastroenterologist, returns a risk score that prioritises high-risk patients for follow-up colonoscopy.

Learn more about ColoPro →
Clinical and scientific foundation

Built on a decade of peer-reviewed proteomics research.

Sangui Bio operates from the Kolling Institute at Royal North Shore Hospital, a partnership between the Northern Sydney Local Health District and the University of Sydney. The work is grounded in foundational discoveries about blood biochemistry, published across a decade of peer-reviewed research.

0
Peer-reviewed publications (2018–2026)
0
Patent families. US granted, international pending
0
Years of medical research at the Kolling Institute
Our clinical network → Our publications →
Team

The people building this.

Dr. Ben Herbert
Co-Founder, CSO

Dr. Ben Herbert

40 years in protein chemistry and proteomics. Co-founder of two ASX-listed biotechs. H-index 41, 100+ publications.

Alan Liddle
Co-Founder, Executive Chairman

Alan Liddle

Senior executive with extensive experience in capital raising, governance and biotech commercialisation.

Dr. Elisabeth Karsten
Co-Founder, Principal Scientist

Dr. Elisabeth Karsten

PhD biochemist whose work established red blood cells as dynamic reservoirs of cytokines — a foundational discovery for the platform.

Meet the full team →
Partner with us

Working with clinicians, researchers, and investors.

Sangui Bio is raising to advance ColoPro through clinical validation. We work with gastroenterology practices, clinical research partners, and strategic investors.

Contact Sangui Bio → Investor information